You should restart adalimumab (or switch to another biologic/targeted synthetic DMARD) immediately
After successful disease control with adalimumab followed by failure of methotrexate monotherapy for 5 months, you need to return to biologic therapy—either resuming adalimumab or switching to an alternative biologic/targeted synthetic DMARD with a different mechanism of action. 1
Why This Approach
Your clinical scenario represents a clear treatment failure: you had documented response to a TNF inhibitor (adalimumab), switched to a less potent therapy (methotrexate monotherapy), and now have 5 months of inadequate disease control. This is not a case of primary methotrexate failure—it's inappropriate de-escalation from effective therapy.
The Evidence Supporting Immediate Biologic Restart
Delayed biologic therapy worsens long-term outcomes: Research demonstrates that a 52-week delay in adding adalimumab to methotrexate led to significantly worse radiographic, functional, and clinical outcomes at 5 years compared to immediate combination therapy 2. Your 5-month delay is already causing preventable disease progression.
Current guidelines strongly recommend biologic therapy after conventional DMARD failure: The 2026 Pan American League guidelines explicitly state that after inadequate response to conventional synthetic DMARDs, switching to biologics or targeted synthetic DMARDs is strongly recommended 1.
Your Treatment Options (in order of preference)
Option 1: Resume Adalimumab (Preferred)
- You already know this works for you
- Proven safety profile in your case
- Fastest path back to disease control
- Add methotrexate as combination therapy unless contraindicated—biologics work better with methotrexate co-medication 1
Option 2: Switch to Different Mechanism of Action
If you cannot resume adalimumab (cost, access, or other barriers), consider:
- IL-6 inhibitors (tocilizumab, sarilumab)
- JAK inhibitors (if <65 years old without cardiovascular risk factors or smoking history) 1
- Abatacept
- Rituximab
The guidelines support both "cycling" (another TNF inhibitor) and "swapping" (different mechanism), but insufficient evidence exists to definitively favor one over the other 1.
Critical Pitfalls to Avoid
Do not continue optimizing methotrexate dosing at this point. While the ACR guidelines suggest maximizing methotrexate before adding biologics 3, this applies to patients who haven't yet tried biologics. You've already proven that:
- Adalimumab controls your disease
- Methotrexate alone does not (5 months is adequate trial)
Do not delay further. Every month of uncontrolled disease activity increases irreversible joint damage. The research shows baseline disease activity and time-averaged disease activity are the strongest predictors of radiographic progression 4.
If Cost/Access Is the Issue
If you switched from adalimumab to methotrexate due to cost or access rather than clinical reasons:
- Advocate aggressively for biologic coverage—document the treatment failure
- Consider biosimilar adalimumab if available (lower cost)
- If absolutely forced to use conventional DMARDs temporarily, add leflunomide to methotrexate or try triple therapy (methotrexate + sulfasalazine + hydroxychloroquine) 1, but understand this is suboptimal given your history
The Bottom Line
You need biologic therapy now. Methotrexate monotherapy has failed after 5 months, you have a history of excellent response to adalimumab, and continuing current therapy risks permanent joint damage. Resume adalimumab with methotrexate combination therapy, or switch to an alternative biologic/targeted synthetic DMARD if adalimumab is not accessible.